行情

MGNX

MGNX

MacroGenics
NASDAQ

实时行情|Nasdaq Last Sale

9.96
-0.47
-4.51%
交易中 14:31 01/29 EST
开盘
10.50
昨收
10.43
最高
10.51
最低
9.96
成交量
10.74万
成交额
--
52周最高
32.32
52周最低
7.43
市值
4.88亿
市盈率(TTM)
-2.7627
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MGNX 新闻

  • 欧洲议会表决通过“脱欧”协议 为英国脱欧铺平道路
  • 新浪财经.1小时前
  • 美国12月份二手房签约量录得2010年以来最大降幅
  • 新浪财经.2小时前
  • 午盘:联储决议在即 美股维持涨势
  • 新浪美股.2小时前
  • 冠状病毒阴云笼罩 苹果公司“复苏”之路前景存疑
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
-0.07%
制药与医学研究
+0.36%

热门股票

名称
价格
涨跌幅

MGNX 简况

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
展开

Webull提供MacroGenics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。